Reported 2 days ago
AstraZeneca has entered a $5.3 billion AI-led research agreement with China's CSPC Pharmaceutical Group to develop therapies for chronic conditions. This collaboration aims to leverage AI for discovering new treatments, particularly for immunological diseases, and reflects AstraZeneca's strategy to enhance its presence in the Chinese market amid previous challenges. The deal includes an upfront payment and milestone payments for successful development and sales.
Source: YAHOO